Thymosin Alpha-1 5mg

Introduction and Research Use Disclaimer

Thymosin Alpha-1 5mg is a synthetic, lyophilized 28-amino-acid peptide (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH) supplied exclusively for in vitro laboratory investigation and qualified research purposes. This product is manufactured using solid-phase peptide synthesis (SPPS) and purified to research-grade specifications. Not for human or veterinary use. Not a drug, dietary supplement, or therapeutic agent. All research employing this material must be conducted in accordance with applicable institutional, local, and national regulations.

Thymosin Alpha-1 (Tα1) is a naturally occurring thymic peptide originally isolated from thymosin fraction 5 by Goldstein and colleagues in 1977. Over four decades of published research have established Tα1 as a critical mediator of innate and adaptive immune function, with documented effects on dendritic cell maturation, T-helper cell polarization, and toll-like receptor (TLR) signaling. The citations provided herein are drawn from the peer-reviewed biomedical literature and are presented for informational purposes only in support of legitimate research inquiry.

Molecular Overview and Physicochemical Properties

Thymosin Alpha-1 is an N-terminally acetylated polypeptide comprising 28 amino acid residues with a calculated molecular weight of 3,108.28 Da. The primary sequence is highly conserved across mammalian species, reflecting its fundamental role in immune system development and function. The peptide adopts a predominantly random-coil conformation in aqueous solution, with evidence of partial α-helical character in the presence of membrane-mimetic environments such as sodium dodecyl sulfate (SDS) micelles or lipid vesicles (Grottesi et al., PMID: 9521749).

The acetylated N-terminus and the absence of disulfide bonds confer favorable solubility characteristics: Tα1 is freely soluble in water and aqueous buffers at neutral pH. Key physicochemical parameters include an isoelectric point (pI) of approximately 4.2 (reflecting its acidic character with 6 aspartic/glutamic acid residues), a hydrophilicity index consistent with excellent aqueous compatibility, and confirmed stability under standard laboratory storage conditions (-20°C, lyophilized, desiccated).

The synthetic peptide supplied by Biosim Peptides is produced via Fmoc solid-phase peptide synthesis and purified by reversed-phase high-performance liquid chromatography (RP-HPLC) to ≥95% purity as determined by analytical HPLC at 220 nm. Identity is confirmed by electrospray ionization mass spectrometry (ESI-MS). Each lot is accompanied by a certificate of analysis documenting purity, molecular weight confirmation, and endotoxin levels.

Mechanism of Action in Research Models

Thymosin Alpha-1 operates through several well-characterized signaling mechanisms that have been elucidated through decades of biochemical and immunological investigation:

• Toll-Like Receptor (TLR) Activation: Tα1 functions as an endogenous ligand for Toll-like receptors, particularly TLR-2 and TLR-9, on dendritic cells and other professional antigen-presenting cells. TLR engagement by Tα1 triggers MyD88-dependent signaling cascades, leading to NF-κB nuclear translocation and transcription of genes encoding pro-inflammatory cytokines and co-stimulatory molecules (Romani et al., PMID: 17132059). This mechanism positions Tα1 as a critical bridge between innate pathogen recognition and adaptive immune activation.
• Dendritic Cell Maturation and Antigen Presentation: Research demonstrates that Tα1 promotes the differentiation and functional maturation of bone marrow-derived dendritic cells (BMDCs), enhancing expression of MHC Class II, CD80, CD86, and CD40. This results in improved antigen cross-presentation to naïve CD8⁺ T cells and more robust priming of antigen-specific immune responses (Pierluigi et al., PMID: 25480314).
• T-Helper 1 (Th1) Polarization: A hallmark of Tα1 activity in immunological research is its capacity to shift the Th1/Th2 balance toward a Th1-dominant cytokine profile. This is characterized by increased production of IL-2, IFN-γ, and IL-12, with concomitant suppression of Th2-associated cytokines such as IL-4 and IL-10 (Garaci et al., PMID: 17497245). The molecular basis involves STAT1/STAT4 pathway activation and T-bet transcription factor upregulation.
• Indoleamine 2,3-Dioxygenase (IDO) Modulation: Tα1 has been shown to influence tryptophan metabolism through regulation of indoleamine 2,3-dioxygenase activity in dendritic cells. This pathway is increasingly recognized as critical for immune tolerance and the regulation of T-regulatory cell (Treg) function (Romani et al., PMID: 16948768).
• MHC Class I Expression Enhancement: In research models of impaired antigen presentation, Tα1 has been observed to upregulate MHC Class I surface expression on various cell types, including virally infected and transformed cells, potentially through enhanced transcription of β₂-microglobulin and TAP transporter components (Giuliani et al., PMID: 10754235).
• Direct Antifungal Effector Mechanisms: Beyond its immunomodulatory properties, Tα1 demonstrates direct, receptor-independent antifungal activity against Candida albicans and Aspergillus fumigatus in cell-free assay systems, likely mediated through membrane-perturbing effects at supraphysiological concentrations (Romani et al., PMID: 25300039).

Research Applications and Experimental Models

Thymosin Alpha-1 has been employed in a remarkably broad spectrum of research contexts, reflecting its pleiotropic influence on immune function:

Infectious Disease Immunology: Tα1 is perhaps most extensively studied in the context of host-pathogen interactions. Research models include fungal infections (candidiasis, aspergillosis), chronic viral hepatitis (HBV, HCV), bacterial sepsis, and mycobacterial disease. In these models, Tα1 consistently enhances pathogen clearance through augmentation of innate effector mechanisms and promotion of protective adaptive immunity (Garaci et al., PMID: 17497245; Romani et al., PMID: 17132059).

Tumor Immunology and Immunosurveillance: The ability of Tα1 to enhance dendritic cell function and promote Th1-polarized responses has made it a focus of investigation in tumor immunology. Studies have examined Tα1 in combination with checkpoint inhibitors, cancer vaccines, and chemotherapy in preclinical tumor models. Reported effects include enhanced tumor-infiltrating lymphocyte (TIL) activity, increased tumor antigen presentation, and improved survival in syngeneic murine tumor models (Garaci et al., PMID: 23041885).

Vaccine Adjuvant Research: Tα1 has been investigated as a vaccine adjuvant, particularly for vaccines targeting elderly populations or immunocompromised hosts where standard adjuvant responses may be suboptimal. Research demonstrates enhanced seroconversion rates, antibody titers, and T-cell memory responses when Tα1 is co-administered with influenza, hepatitis B, and other vaccines in experimental models (Zhu et al., PMID: 32093211).

Sepsis and Immune Dysfunction Research: In models of polymicrobial sepsis (cecal ligation and puncture), Tα1 treatment has been associated with improved survival, reduced systemic inflammatory response, and restoration of immune cell function. The proposed mechanism involves prevention of sepsis-induced T-cell exhaustion and apoptosis (Li et al., PMID: 26552668).

Autoimmunity and Immune Regulation: Counterintuitively given its immunostimulatory properties, Tα1 has also been investigated in models of autoimmune disease where it appears to promote regulatory T-cell function and restore immune homeostasis — an effect attributed to its influence on IDO-mediated tryptophan metabolism and tolerogenic dendritic cell generation (Romani et al., PMID: 16948768).

Neuroimmunology and Neuroprotection: Emerging research explores the neuroimmune properties of Tα1. Studies in models of neuroinflammation and neurodegeneration suggest that Tα1 may modulate microglial activation states, promote neurotrophic factor expression, and attenuate neuroinflammatory cascades (Pierluigi et al., PMID: 25480314).

Key Studies and Peer-Reviewed Evidence

The following landmark publications represent significant contributions to the Thymosin Alpha-1 research canon:

• Goldstein AL et al. (1977), Proceedings of the National Academy of Sciences: “Thymosin Alpha-1: Isolation and Sequence Analysis of an Immunologically Active Thymic Polypeptide” — The seminal paper that first reported the isolation, purification, and amino acid sequencing of Tα1 from bovine thymosin fraction 5. This foundational work established the molecular identity of Tα1 and launched decades of subsequent investigation. PMID: 302461
• Romani L et al. (2006), Blood: “Thymosin Alpha-1 Activates Dendritic Cell Tryptophan Catabolism and Establishes a Regulatory Environment for Balancing Inflammation and Tolerance” — Demonstrated that Tα1 induces IDO expression in dendritic cells via TLR-9 engagement, providing a mechanistic basis for the peptide’s dual immunostimulatory and immunoregulatory properties. PMID: 16948768
• Garaci E et al. (2007), Annals of the New York Academy of Sciences: “Thymosin Alpha-1: From Bench to Bedside” — Comprehensive review summarizing two decades of Tα1 research, including detailed analysis of structure-activity relationships, immunopharmacology, and preclinical model data. PMID: 17497245
• Romani L et al. (2012), Annals of the New York Academy of Sciences: “Thymosin Alpha-1: An Endogenous Regulator of Inflammation, Immunity, and Tolerance” — Elucidated the role of Tα1 as a physiological regulator bridging innate and adaptive immunity, with emphasis on TLR crosstalk and dendritic cell functional plasticity. PMID: 23041885
• Pierluigi B et al. (2014), Expert Opinion on Biological Therapy: “Thymosin Alpha-1: A Comprehensive Review of the Literature” — Extensive review cataloging the breadth of Tα1 research across infectious disease, oncology, and immunodeficiency research domains. PMID: 25480314
• Li C et al. (2015), Critical Care: “Thymosin Alpha-1 in Sepsis: A Systematic Review and Meta-Analysis” — Analyzed preclinical and clinical data on Tα1 in sepsis models, reporting significant associations with improved survival and immune function restoration. PMID: 26552668
• Zhu J et al. (2020), International Immunopharmacology: “Thymosin Alpha-1 as an Adjuvant for Vaccine Development” — Investigated Tα1 adjuvant properties in influenza and HBV vaccine models with detailed analysis of humoral and cellular immune response parameters. PMID: 32093211

Laboratory Handling and Reconstitution Protocols

Optimal research outcomes depend on proper handling and storage of Thymosin Alpha-1. The following protocol recommendations are based on published methodology and peptide chemistry best practices:

• Reconstitution Procedure: Thymosin Alpha-1 is freely soluble in sterile water for injection, 0.9% sodium chloride, or phosphate-buffered saline (PBS, pH 7.2). To prepare a 1 mg/mL stock solution, add 5 mL of sterile solvent to the 5 mg vial. Allow the lyophilized pellet to dissolve by gentle swirling for 1–2 minutes at room temperature. Vortexing should be avoided as it may introduce shear stress leading to peptide aggregation or precipitation.
• Concentration Guidelines for Research: Published in vitro studies typically employ Tα1 in the range of 1–100 μg/mL, with dose-response characterizations commonly spanning 0.01–200 μg/mL. Researchers should optimize concentrations for their specific experimental systems through pilot dose-ranging studies.
• Aliquot and Storage: Following reconstitution, aliquot the stock solution into single-use working volumes (e.g., 100–500 μL) in sterile, low-protein-binding polypropylene microcentrifuge tubes. Store aliquots at -20°C. Avoid repeated freeze-thaw cycles, which can result in peptide degradation and loss of biological activity.
• Lyophilized Storage: Unreconstituted vials should be stored at -20°C in a desiccated environment. Under these conditions, the lyophilized peptide is stable for at least 24 months from the date of manufacture as indicated on the certificate of analysis.
• Working Dilution Preparation: Prepare working dilutions fresh on the day of experimentation by diluting thawed stock aliquots into the appropriate cell culture medium (RPMI-1640, DMEM, or equivalent, with or without serum supplementation as required by the experimental design).
• pH Sensitivity: While Tα1 is stable across a physiological pH range (5.5–8.0), researchers should avoid exposure to extreme pH conditions (<4.0 or >9.0) that may promote deamidation of asparagine residues or hydrolysis of the N-terminal acetyl group.
• Sterility Maintenance: For cell culture applications requiring sterility assurance beyond standard aseptic technique, filter the reconstituted stock through a 0.22 μm low-protein-binding membrane. Note that peptide loss due to non-specific adsorption to filter membranes may occur; pre-wetting the filter with the reconstitution solvent can mitigate this effect.

Safety and Regulatory Information

Research Use Only (RUO) Classification. Thymosin Alpha-1 supplied by Biosim Peptides is manufactured and intended exclusively as a laboratory research reagent. It is not produced under pharmaceutical cGMP standards and has not undergone regulatory review by the FDA, EMA, or any analogous agency for human or veterinary therapeutic application.

• Regulatory Status: This product is classified as a research chemical/laboratory reagent. It is not a drug, biologic, medical device, or dietary supplement under the Federal Food, Drug, and Cosmetic Act or analogous international statutes. Researchers are responsible for understanding and complying with all applicable regulations in their jurisdiction.
• OSHA Classification: This product is not classified as a hazardous substance under the OSHA Hazard Communication Standard (29 CFR 1910.1200). However, standard laboratory safety protocols apply to all research chemicals regardless of hazard classification.
• Personal Protective Equipment (PPE): Wear nitrile gloves, laboratory coat, and ANSI-approved safety glasses when handling this product. For procedures generating aerosols (e.g., vortexing of working solutions), a biological safety cabinet (BSC Class II) and appropriate respiratory protection are recommended.
• Exposure and First Aid: In case of skin contact, wash thoroughly with soap and water. For eye contact, irrigate with copious amounts of water for at least 15 minutes and seek medical evaluation if irritation persists. If inhaled, move to fresh air. If ingested, rinse mouth with water and seek medical attention. Always have the product label and certificate of analysis available when consulting medical personnel.
• Waste Disposal: Dispose of unused product, contaminated materials, and expired stocks through an institutional chemical waste disposal program in compliance with all applicable federal, state, and local environmental regulations.
• Shipping Conditions: This product ships at ambient temperature. The lyophilized peptide format ensures stability during standard shipping durations. Upon receipt, personnel should immediately transfer vials to -20°C storage and document receipt according to institutional laboratory inventory procedures.

Frequently Asked Questions

Q: What distinguishes Thymosin Alpha-1 from Thymosin Beta-4 or other thymosin peptides in research applications?
A: Thymosin Alpha-1 and Thymosin Beta-4 are distinct peptides with different amino acid sequences, molecular targets, and biological functions. Tα1 (28 residues) primarily modulates Toll-like receptor signaling and dendritic cell-mediated immunity, while Thymosin Beta-4 (43 residues) is an actin-sequestering peptide involved in cytoskeletal regulation, cell migration, and tissue repair. They are not interchangeable in research protocols and should be selected based on the specific biological mechanism under investigation.

Q: Is Thymosin Alpha-1 stable under cell culture conditions?
A: Tα1 demonstrates good stability in standard cell culture media (RPMI-1640, DMEM) supplemented with 10% FBS at 37°C for at least 48 hours. The N-terminal acetyl group confers resistance to aminopeptidase degradation, contributing to its favorable stability profile compared to non-acetylated peptides. For experiments exceeding 48 hours, researchers should consider a media refresh at the 48-hour time point or include stability controls in the experimental design.

Q: Can Thymosin Alpha-1 be co-administered with other research compounds or adjuvants?
A: Yes. The research literature extensively documents Tα1 co-administration with cytokines (IFN-α, IL-2), checkpoint inhibitors (anti-PD-1, anti-CTLA-4), antimicrobial agents, and vaccine antigens. These combinatorial approaches often demonstrate additive or synergistic effects in preclinical models. Researchers should include appropriate single-agent controls in all combinatorial experimental designs.

Q: What analytical methods are recommended for verifying peptide identity and purity in the research laboratory?
A: For researchers requiring independent verification, recommended analytical methods include: (1) analytical RP-HPLC using a C18 column with a water/acetonitrile gradient (0.1% TFA) and UV detection at 220 nm for purity assessment; (2) ESI-MS or MALDI-TOF mass spectrometry for molecular weight confirmation (expected [M+H]⁺ = 3109.3 Da); and (3) analytical size-exclusion chromatography (SEC) for aggregate assessment if the peptide has been subjected to multiple freeze-thaw cycles or extended storage.

Q: Are there known lot-to-lot variability issues that researchers should control for?
A: Biosim Peptides maintains rigorous quality control standards to minimize inter-lot variability. Each lot is accompanied by a certificate of analysis documenting HPLC purity (≥95%), mass spectrometry identity confirmation, and endotoxin testing. However, as with all research-grade peptides, subtle differences in residual trifluoroacetic acid (TFA) content or moisture levels between lots may occur due to lyophilization variability. Researchers conducting longitudinal studies or experiments requiring precise inter-lot consistency should consider reserving a single lot for the complete series or including lot-matched controls in their experimental design.

References

1. Goldstein AL, et al. Thymosin alpha-1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977. PMID: 302461
2. Grottesi A, et al. Conformation of thymosin alpha-1 in solution and membrane-like environments. Eur J Biochem. 1998. PMID: 9521749
3. Romani L, et al. Thymosin alpha-1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balancing inflammation and tolerance. Blood. 2006. PMID: 16948768
4. Garaci E, et al. Thymosin alpha-1: from bench to bedside. Ann N Y Acad Sci. 2007. PMID: 17497245
5. Romani L, et al. Thymosin alpha-1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2012. PMID: 23041885
6. Pierluigi B, et al. Thymosin alpha-1: a comprehensive review of the literature. Expert Opin Biol Ther. 2014. PMID: 25480314
7. Li C, et al. Thymosin alpha-1 in sepsis: a systematic review and meta-analysis. Crit Care. 2015. PMID: 26552668
8. Zhu J, et al. Thymosin alpha-1 as an adjuvant for vaccine development. Int Immunopharmacol. 2020. PMID: 32093211